Worth Observing Stocks: Edge Therapeutics, Inc. (NASDAQ:EDGE) & Summit Midstream Partners, LP (NYSE:SMLP)

5

Edge Therapeutics, Inc. (NASDAQ:EDGE)

Edge Therapeutics, Inc. is a biotechnology company which discovers, develops and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate which are in preclinical trial EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage, EG-1964, to prevent recurrent bleeding after treatment for cSDH and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. is headquartered in Berkeley Heights, New Jersey.

Edge Therapeutics, Inc. (NASDAQ:EDGE)’s Financial Overview

Edge Therapeutics, Inc. (NASDAQ) declined -6.35% yesterday to close its trading session at $0.4. The company has 1 year Price Target of $1. Edge Therapeutics, Inc. has 52-Week high of $17.77 and 52-Week Low of $0.28. The stock touched its 52-Week High on 17.77 and 52-Week Low on 0.28. The stock traded with the volume of 725834 shares yesterday. The firm shows the market capitalization of $12.93 Million.

Edge Therapeutics, Inc. (NASDAQ) reported its last quarterly earnings on 6/29/2018 where the firm reported its Actual EPS of $-0.41/share against the analyst consensus estimate of $-0.53/share. The difference between the actual and expected EPS is $0.12 a share with a surprise factor of 22.6%.

The firm is trading with SMA20 of -5.86 Percent, SMA50 of -6.8 Percent and SMA200 of -49.37 percent. Edge Therapeutics, Inc. has P/S value of 0 while its P/B value stands at 0.4. Similarly, the company has Return on Assets of -81.4 percent, Return on Equity of -120.9 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 1 analysts offering 12-month price forecasts for Edge Therapeutics Inc have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a +153.10% increase from the last price of 0.40.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Summit Midstream Partners, LP (NYSE:SMLP)

Summit Midstream Partners, LP is focused on owning and operating midstream energy infrastructure that are located in unconventional resource basins. It provides fee-based natural gas gathering and compression services in two unconventional resource basins: the Piceance Basin and the Fort Worth Basin. Summit Midstream Partners, LP is headquartered in Dallas, Texas.

Summit Midstream Partners, LP (NYSE:SMLP)’s Financial Outlook

The 10 analysts offering 12-month price forecasts for Summit Midstream Partners LP have a median target of 15.50, with a high estimate of 23.00 and a low estimate of 11.00. The median estimate represents a +20.62% increase from the last price of 12.85.

Summit Midstream Partners, LP is expected* to report earnings on 02/21/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.24. The reported EPS for the same quarter last year was $0.25.

According to Zacks Investment Research, Summit Midstream Partners, LP has a Consensus Recommendation of 3. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0.31% and closed its last trading session at $12.85. The company has the market capitalization of $969.4 Million. The stock has 52-week high of $20.7 and 52-Week low of $10.04. The firm touched its 52-Week high on 20.75 and 52-Week low on 10.04. The company has volume of 350964 shares. The company has a total of 75.44 Million shares outstanding.

Summit Midstream Partners, LP (NYSE) in the last quarter reported its actual EPS of $0.64/share where the analyst estimated EPS was $0.25/share. The difference between the actual and Estimated EPS is $0.39. This shows a surprise factor of 156 percent.

The company has YTD performance of 27.86 percent. Beta for Summit Midstream Partners, LP stands at 1.87 while its ATR (average true range) is 0.48. The company has Weekly Volatility of 3.53%% and Monthly Volatility of 3.03%%.

Summit Midstream Partners, LP has distance from 20-day Simple Moving Average (SMA20) of -1.16%, Distance from 50-Day Simple Moving Average of 2.87 percent and Distance from 200-Day Simple Moving Average of -13.94%.

The Company currently has ROA (Return on Assets) of -1.5 percent, Return on Equity (ROE) of -4.6 Percent and Return on Investment (ROI) of -2.1% with Gross margin of 62 percent and Operating & Profit margin of -8.7% and -8.9% respectively.

SHARE